Hims & Hers Q2 Report: Mixed Results and Cautious Guidance, Shares Fall 12%

Hims & Hers (NYSE:HIMS) reported Q2 revenue of $544.8 million, up 73% YoY, but short of estimates. Earnings per share of $0.17 beat expectations. The company guided Q3 revenue in the range of $570 million to $590 million, below estimates. Shares fell 12% before the market opened on Tuesday.

Hims & Hers Health (NYSE:HIMS) reported its second-quarter (Q2) results on Monday, with revenue coming in at $544.8 million, a 73% year-over-year (YoY) increase but short of Wall Street's expectations. The company's shares fell by 12% before the market opened on Tuesday.

The telehealth company's adjusted earnings per share (EPS) of $0.17 exceeded the consensus estimate of $0.15. However, the revenue figure fell $7.2 million short of the $552 million expected by analysts. Despite the revenue miss, the company reported adjusted EBITDA of $82 million, more than doubling from last year's $39.3 million.

For the third quarter (Q3), Hims & Hers guided revenue between $570 million and $590 million, which was below the StreetAccount's forecast of $583 million. The company also provided a Q3 EBITDA guidance of $60 million to $70 million, falling short of the $77.1 million forecast by StreetAccount.

The company continues to face scrutiny over its distribution of compounded GLP-1s, which are cheaper, unapproved versions of popular diabetes and weight-loss drugs. The FDA has previously resolved supply issues, but some telehealth companies, including Hims & Hers, continue to offer personalized doses.

Investors remained cautious despite the strong profit metrics, likely due to the revenue miss and ongoing regulatory concerns. Analysts are divided on the stock's future prospects, with the average target price at $48.49, ranging from $28.00 to $85.00 [2].

The sustainability of the stock's immediate price movement will depend on management's commentary during the quarterly call with investors at 5 p.m. ET. Investors should also watch for changes in earnings estimate revisions, which can provide insights into the stock's near-term performance [4].

References:
[1] https://seekingalpha.com/article/4808621-hims-and-hers-buy-earnings-dip-slowly
[2] https://www.tradingview.com/news/gurufocus:259e0cac6094b:0-hims-hers-stock-nosedives-after-q2-revenue-miss-despite-73-growth/
[3] https://www.cnbc.com/2025/08/04/hims-hers-hims-q2-earnings-2025.html
[4] https://www.nasdaq.com/articles/hims-hers-health-inc-hims-misses-q2-earnings-and-revenue-estimates